We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Part I. General subjects
-
1. Need for drug delivery systems 1
- Prof. Ana Catarina Silva
-
2. Need for drug delivery systems 2
- Prof. João Nuno Moreira
-
3. Routes of drug delivery
- Prof. Dr. Sven Stegemann
-
4. Transporters in drug delivery
- Dr. Pravin Shende
-
5. The theory and applications of controlled release principles
- Dr. Michael J. Rathbone
- Part II. Routes for drug delivery
-
6. Oral drug delivery
- Dr. Vineet Kumar Rai
-
7. Transdermal drug delivery
- Prof. Sabine Szunerits
-
8. Pulmonary drug delivery
- Prof. Anthony J. Hickey
-
9. Gastrointestinal drug delivery
- Prof. Susan Hua
-
10. Mucoadhesive drug delivery systems
- Dr. Panoraia I. Siafaka
-
11. Ocular drug delivery
- Prof. Emily Dosmar
-
12. Vaginal and uterine drug delivery
- Prof. José Luis Arias Mediano
-
13. Drug-eluting implants
- Dr. Aliasger K. Salem
- Part III. Materials for drug delivery
-
14. Polymers as nanocarriers for controlled drug delivery
- Prof. Dr. Marcelo Calderón
-
15. Polymeric gels for drug delivery
- Dr. G. Roshan Deen
- Ms. Dora Safar
-
16. Liposomes as a drug delivery system
- Dr. G. Roshan Deen
- Ms. Bushra Hasan
- Ms. Renad AlAnsari
-
17. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)
- Prof. Ana Catarina Silva
-
18. Micellar drug delivery
- Prof. Francesco Cellesi
-
19. Nanocrystals in drug delivery
- Prof. Eliana Souto
-
20. Layer-by-layer assemblies for drug delivery
- Prof. Szczepan Zapotoczny
-
21. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
22. Inorganic porous drug delivery carriers
- Prof. Jessica Rosenholm
- Part IV. Specifics of drug delivery
-
23. Delivery of genes and nucleotides
- Prof. Esam Yahya
-
24. Vaccine delivery
- Prof. Sevda Şenel
- Part V. Drug delivery in various diseases
-
25. Drug delivery for cancer therapeutics
- Prof. Tejraj Aminabhavi
-
26. Nanomedicines for brain diseases
- Prof. Giovanni Tosi
-
27. Drug delivery to the colon
- Prof. Susan Hua
-
28. Role of the lymphatic system in drug absorption
- Dr. Kishor M. Wasan
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Subject introduction
- Nanosystems
- Nanosystems advantages
- Lipid nanoparticles - definition
- Lipid nanoparticles - advantages
- Lipid nanoparticles - examples of solid lipids
- Lipid nanoparticles - examples of liquid lipids
- Lipid nanoparticles - emulsifiers
- Types of lipid nanoparticles
- Differences between SLN and NLC
- Solid lipid nanoparticles (SLN)
- Models for molecules incorporation in SLN
- Solid lipid nanoparticles (SLN): limitations
- Nanostructured lipid carriers (NLC)
- Models for molecules incorporation in NLC
- Most used production methods for SLN/NLC
- Production methods
- Examples of applications
- Examples of applications: cutaneous use
- Examples of applications: semi-solid systems
- Direct increase of SLN/NLC dispersions consistency (1)
- Association of SLN/NLC with semi-solid formulations
- Direct increase of SLN/NLC dispersions consistency (2)
- Examples of research studies
- Examples of research studies: results
- Nose-to-brain route: different routes
- Nose-to-brain route
- Nose-to-brain route: examples of research studies
- Nose-to-brain route: quality by design
- Examples of research studies: QTPP
- Critical material attributes (CMAs) and critical process parameters (CPPs)
- Optimization of formulation variables or CMAs (1)
- Optimization of formulation variables or CMAs (2)
- Optimization of instrumental parameters or CPPs
- Effects of CPPs on dependent variables
- Effects of CPPs on dependent variables: EE
- Effects of CPPs on dependent variables: PDI & ZP
- Biocompatibility studies
- Nose-to-brain route: examples of research studies
- Drug deposition in the olfactory region
- Conclusion
- Extra reading
- Thank you
Topics Covered
- Introduction to the nanosystems
- Definition of lipid nanoparticles
- Types of lipid nanoparticles
- Solid lipid nanoparticles (SLN)
- Nanostructured lipid carriers (NLC)
- SLN and NLC production methods
- Examples of applications: cutaneous use and nose-to-brain route
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Silva, A.C. (2023, October 31). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/PFKY1980.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)
Published on October 31, 2023
23 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, My name is
Ana Catarina Silva and I'm
an associate professor
at University Fernando
Pessoa and a researcher
at UCIBIO Faculty of Pharmacy
University of Porto, Portugal.
Today I will talk about the
two types of lipid
nanoparticles,
namely solid lipid
nanoparticles or SLN,
and nanostructured
lipid carriers or NLC.
0:27
I will start my presentation
with an overview
of nanosystems followed
by a detailed description
of SLN and NLC.
Finally, I will present
some research results
with this type of
lipid nanoparticles
and end with some conclusions.
0:47
Formulation limitations
in conventional
pharmaceutical dosage forms
are related to several factors
such as synthesis
of new lipophilic drug molecules
belonging to BCS
classes II and IV,
the development of
therapeutic proteins
that can be degraded by
the body environment,
and the development of
nucleic acid based therapies
which shows limitations related
to their molecular
characteristics.
All these factors give rise
to bioavailability problems.
1:23
Among the strategies
that have been used
to improve drug bioavailability,
the most explored are the
drug delivery systems,
in particular the nanosystems.
As it can be seen in this scale,
they are nanosized
colloidal carriers
which are 100 to 10000
smaller than human cells.
Hide